['neovascular age-related macular degeneration', 'wet macular degeneration']
['dorzolamide-timolol']

        Inclusion Criteria:

          1. Active choroidal neovascularization (CNV) due to AMD.

          2. Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months
             and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during
             this period.

          3. Baseline CST ≥ 270 µm on SD-OCT automated retinal thickness map.

          4. Injection of the same anti-VEGF agent at each of the two visits immediately preceding
             study enrollment.

          5. Time interval of 5 weeks (± 1 week) between visits for at least two visits immediately
             preceding study enrollment.

          6. Subjects of either gender aged ≥ 45 years.

          7. Provide written informed consent

          8. Ability to comply with study and follow-up procedures and return for study visits.

        Exclusion Criteria:

          1. History of uveitis.

          2. Presence of intraocular inflammation, significant epiretinal membrane (causing
             distortion of macular anatomy per investigator discretion), significant vitreomacular
             traction (per investigator discretion), macular hole, or vitreous hemorrhage.

          3. Any ophthalmic surgery within previous 6 months, including cataract extraction.

          4. Any history of vitrectomy or glaucoma surgery (e.g., trabeculectomy, tube shunt).

          5. Current prescription eye drop usage (e.g., glaucoma drops, corticosteroid drops,
             etc.).

          6. Any contraindication for topical use of a beta-blocker (e.g., bradycardia,
             decompensated heart failure, chronic obstructive pulmonary disease, reactive airway
             disease, asthma, etc.).

          7. Any history of sulfonamide allergy.
      